Thrombotic microangiopathy (TMA) is a group of diseases that are life-threatening and can lead to end organ damage (EOD) due to ischemia caused by microthrombi in capillaries and arterioles. TMAs can affect any organ system but usually affect the kidney, intestines, and nervous system. The triad of TMA is Coombs-negative hemolytic anemia with schistocytes seen on peripheral smear, thrombocytopenia (platelets under 150,000 or a decrease of 25% or more from baseline), and evidence of ischemic EOD. Primary TMAs include Thrombotic Thrombocytopenic Purpura (TTP), Hemolytic Uremic Syndrome (HUS) and atypical HUS (aHUS). Pathophysiologically, all of these diseases are caused by aggregation of von Willebrand Factor (vWF) multimers, via different mechanisms, which eventually leads to thrombus formation. TTP and aHUS benefit from plasma exchange (PEX), whereas HUS is treated symptomatically. Urgent recognition with timely treatment is crucial to managing these potentially life-threatening conditions.
KeywordsTMAaHUSHUSTTP
Brocklebank, V., et al. (2017) Thrombotic Microangiopathy and the Kidney. Clinical Journal of the American Society of Nephrology, 13, 300-317. https://doi.org/10.2215/CJN.00620117
Bommer, M., et al. (2018) The Differential Diagnosis and Treatment of Thrombotic Microangiopathies. Deutsches Arzteblatt International, 115, 327-334. https://doi.org/10.3238/arztebl.2018.0327
George, J.N. and Nester, C.M. (2014) Syndromes of Thrombotic Microangiopathy. The New England Journal of Medicine, 371, 654-666. https://doi.org/10.1056/NEJMra1312353
Garg, A.X., Suri, R.S., Barrowman, N., et al. (2003) Long-Term Renal Prognosis of Diarrhea-Associated Hemolytic Uremic Syndrome: A Systematic Review, Meta-Analysis, and Meta-Regression. JAMA, 290, 1360-1370. https://doi.org/10.1001/jama.290.10.1360
Moake, J.L. (2002) Thrombotic Microangiopathies. The New England Journal of Medicine, 347, 589-602. https://doi.org/10.1056/NEJMra020528
Tran, P.N. (2018) Cobalmin Deficiency Presenting with Thrombotic Microangipathy (TMA) Features: A Systematic Review. Transfusion and Apheresis Science, 57, 102-106. https://doi.org/10.1016/j.transci.2018.01.003
Booth, K.K., et al. (2011) Systemic Infections Mimicking Thrombotic Thrombocytopenic Purpura. American Journal of Hematology, 86, 743-751. https://doi.org/10.1002/ajh.22091
Beckford, R. and Shah, G. (2010) Thrombotic Thrombocytopenic Purpura: A Review of the Disease Entity, Its Clinical and Laboratory Features, and Management Strategies. The Medicine Forum, 12, 12-15. https://doi.org/10.29046/TMF.012.1.005
Blombery, P. and Scully, M. (2014) Management of Thrombotic Thrombocytopenic Purpura: Current Perspectives. Journal of Blood Medicine, 5, 15-23. https://doi.org/10.2147/JBM.S46458
Wu, H.M., et al. (2013) Pulmonary Manifestations in Patients with Thrombotic Thrombocytopenic Purpura at a Community Hospital Setting. Chest, 144, 365A. https://doi.org/10.1378/chest.1703532
George, J.N., et al. (2008) Lessons Learned from the Oklahoma Thrombotic Thrombocytopenic Purpura-Hemolytic Uremic Syndrome Registry. Journal of Clinical Apheresis, 23, 129-137. https://doi.org/10.1002/jca.20169
Jamme, M. and Rondeau, E. (2017) The PLASMIC Score for Thrombotic Thrombocytopenic Purpura. The Lancet Haematology, 4, e148-e149. https://doi.org/10.1016/S2352-3026(17)30024-8
Tsai, H.-M. (2006) Current Concepts in Thrombotic Thrombocytopenic Purpura. Annual Review of Medicine, 57, 419-436. https://doi.org/10.1146/annurev.med.57.061804.084505
Rock, G.A., et al. (1991) Comparison of Plasma Exchange with Plasma Infusion in the Treatment of Thrombotic Thrombocytopenic Purpura. New England Journal of Medicine, 325, 393-397. https://doi.org/10.1056/NEJM199108083250604
George, G.N. (2006) Thrombotic Thrombocytopenic Purpura. New England Journal of Medicine, 364, 1927-1936. https://doi.org/10.1056/NEJMcp053024
Hovinga, J.A.K., et al. (2009) Survival and Relapse in Patients with Thrombotic Thrombocytopenic Purpura. Blood, 115, 1500-1511. https://doi.org/10.1182/blood-2009-09-243790
Westwood, J.-P., et al. (2017) Rituximab Prophylaxis to Prevent Thrombotic Thrombocytopenic Purpura Relapse: Outcome and Evaluation of Dosing Regimens. Blood Advances, 1, 1159-1166. https://doi.org/10.1182/bloodadvances.2017008268
Lee, W.R. (1983) Hemorrhagic Colitis Associated with a Rare Escherichia coli Serotype. The New England Journal of Medicine, 308, 681-685. https://doi.org/10.1056/NEJM198303243081203
Karpman, D., et al. (2017) Haemolytic Uraemic Syndrome. Journal of Internal Medicine, 281, 123-148. https://doi.org/10.1111/joim.12546
Tarr, P.I., et al. (2005) Shiga-Toxin-Producing Escherichia coli and Haemolytic Uraemic Syndrome. The Lancet, 365, 1073-1085. https://doi.org/10.1016/S0140-6736(05)71144-2
Fakhouri, F., et al. (2017) Haemolytic Uraemic Syndrome. The Lancet, 390, 681-696. https://doi.org/10.1016/S0140-6736(17)30062-4
Hossain, M.A., et al. (2018) Atypical Hemolytic Uremic Syndrome: Laboratory Characteristics, Complement-Amplifying Conditions, Renal Biopsy, and Genetic Mutations. Saudi Journal of Kidney Diseases and Transplantation, 29, 276-283. https://doi.org/10.4103/1319-2442.229287
Nickavar, A. and Sotoudeh, K. (2013) Assessment, Treatment and Prevention of Atypical Hemolytic Uremic Syndrome. International Journal of Preventive Medicine, 4, 6-14.
Phillips, E.H., Westwood, J.P., Brocklebank, V., et al. (2016) The Role of ADAMTS-13 Activity and Complement Mutational Analysis in Differentiating Acute Thrombotic Microangiopathies. Journal of Thrombosis and Haemostasis, 14, 175-185. https://doi.org/10.1111/jth.13189
Loirat, C. and Frémeaux-Bacchi, V. (2011) Atypical Hemolytic Uremic Syndrome. Orphanet Journal of Rare Diseases, 6, 60. https://doi.org/10.1186/1750-1172-6-60
Martinez-Barricarte, R., Pianetti, G., Gautard, R., et al. (2008) The Complement Factor H R1210C Mutation Is Associated with Atypical Hemolytic Uremic Syndrome. Journal of the American Society of Nephrology, 19, 639-646. https://doi.org/10.1681/ASN.2007080923
Raina, R., Krishnappa, V., Blaha, T., Kann, T., Hein, W., Burke, L. and Bagga, A. (2019) Atypical Hemolytic-Uremic Syndrome: An Update on Pathophysiology, Diagnosis, and Treatment. Therapeutic Apheresis and Dialysis, 23, 4-21. https://doi.org/10.1111/1744-9987.12763
Parente, R., Clark, S.J., Inforzato, A. and Day, A.J. (2016) Complement Factor H in Host Defense and Immune Evasion. Cellular and Molecular Life Sciences, 74, 1605-1624. https://doi.org/10.1007/s00018-016-2418-4
Noris, M. and Remuzzi, G. (2013) Overview of Complement Activation and Regulation. Seminars in Nephrology, 33, 479-492. https://doi.org/10.1016/j.semnephrol.2013.08.001
Asif, A., Vachharajani, T., Salman, L. and Nayer, A. (2014) A Simplified Approach to the Diagnosis of Atypical HUS: Clinical Considerations and Practical Implication. The Open Urology & Nephrology Journal, 7, 91-94. https://doi.org/10.2174/1874303X01407010091
Salvadori, M. and Bertoni, E. (2013) Update on Hemolytic Uremic Syndrome: Diagnostic and Therapeutic Recommendations. World Journal of Nephrology, 2, 56-76. https://doi.org/10.5527/wjn.v2.i3.56
Nayer, A. and Asif, A. (2016) Atypical Hemolytic-Uremic Syndrome: A Clinical Review. American Journal of Therapeutics, 23, e151-e158. https://doi.org/10.1097/MJT.0b013e31829b59dc